Medicenna Therapeutics Corp.

MDNA

CA58490H1073

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.92 ^CAD	+23.87%		+10.98%	+357.14%

Apr. 24	Medicenna Therapeutics Up 13% After Flagging Presentations	MT
Apr. 16	Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM

Medicenna Therapeutics Corp. Appoints Karen Dawes as Director

September 24, 2019 at 05:46 pm EDT

Medicenna Therapeutics Corp. announced the appointment of Ms. Karen Dawes to the Board of Directors of the company. Ms. Dawes is currently President of Knowledgeable Decisions.

Latest news about Medicenna Therapeutics Corp.

Medicenna Therapeutics Up 13% After Flagging Presentations	Apr. 24	MT
Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM	Apr. 16
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR	Apr. 10	MT
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today	Apr. 09	MT
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine	Apr. 09	MT
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	Apr. 09	MT
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	Apr. 09	CI
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	Apr. 09	MT
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting	Mar. 06	MT
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting	Mar. 06	CI
Medicenna Reports Q3 Net Loss $5.0 Million	Feb. 14	MT
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022	Feb. 14	MT
Medicenna Says First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda in Patients with Advanced Solid Tumors	Feb. 13	MT
Medicenna Brief: Announcing First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors	Feb. 13	MT
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors	Feb. 13	CI
Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab	Jan. 09	MT
Medicenna Brief: Commencing Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab	Jan. 09	MT
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab	Jan. 09	CI
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2%	Dec. 22	MT
Medicenna Therapeutics Extends Period to Exercise Certain Warrants	Dec. 22	MT
Medicenna Brief: Announcing Trading on the OTCQB Under the Symbol MDNAF	Dec. 19	MT
Medicenna Announces "Compelling" Survival Benefit From Phase 2b Study in Recurrent Glioblastoma at NeuroOncology Meeting	Nov. 17	MT
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp	Nov. 17	CI
Medicenna Reports Q2 Net Loss of $0.05 Per Share; Cash Runway Extended Into Q1 of Calendar 2025	Nov. 14	MT

Chart Medicenna Therapeutics Corp.

Duration

Period

More charts

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Companyâs IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Companyâs early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract No: 2709

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.92 CAD

Average target price

9 CAD

Spread / Average Target

+368.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICENNA THERAPEUTICS CORP.	+357.14%	97.44M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.34%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research